drp 1

DRP1 Allosteric-IN-1 (Compound 1) is an allosteric inhibitor of DRP1, with an IC50 of 3.6 μM for the DRP1:MiD49 protein-protein interaction. It is applicable in the study of various diseases associated with mitochondrial fission disorders.

DRP1 Allosteric-IN-2 (Compound 2a) is an allosteric inhibitor of DRP1, exhibiting an IC50 of 4.3 μM for the DRP1:MiD49 protein-protein interaction. This compound is useful for researching diseases associated with mitochondrial fission disorders.

DRP1 Allosteric-IN-3 (Compound 2b) serves as an allosteric inhibitor of DRP1 with an IC50 of 11 μM for inhibiting DRP1:MiD49 protein-protein interactions. It is applicable for studying various diseases associated with mitochondrial division disorders.

Drp1-IN-1 (comp A-7) is a Drp1 protein inhibitor with an IC50 value of 0.91 μM.

Compound P110 (Drp1 peptide inhibitor P110) is a selective Drp1 peptide inhibitor with neuroprotective effects. It inhibits the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and alleviates dopamine neuron loss, dopaminergic terminal damage, and behavioral deficits caused by MPTP. This compound is useful for Alzheimer's disease research. Additionally, Compound P110 reduces mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemia, and myocardial infarction.

Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. It suppresses the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and reduces MPTP-induced loss of dopaminergic neurons, damage to dopaminergic nerve terminals, and behavioral defects, making it useful for Alzheimer's disease research. Furthermore, Drp1 peptide inhibitor P110 TFA mitigates mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.

DRP1i27, a potent human dynamin-related protein 1 (Drp1) inhibitor, targets the GTPase site of Drp1, forming hydrogen bonds with Gln34 and Asp218. It mitigates Drp1-mediated mitochondrial fission in cell line models and offers protection against simulated ischemia-reperfusion injury.

P110 TFA is a dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity.

Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.

P110 heptapeptide is a specific peptide inhibitor that interacts with Drp1/Fis1 (IC₅₀=1.8 μM). By competitively blocking the binding of Drp1 to Fis1, P110 heptapeptide inhibits pathological mitochondrial fission while preserving the physiological function of Drp1, thereby reducing pathological features in numerous models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide exhibits neuroprotective, anti-inflammatory, and anti-sepsis activity and can be used in research on neurodegenerative diseases and conditions associated with mitochondrial dysfunction.